Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Protected Environment Rooms for AML and MDS

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* AML or high-risk MDS (\> 10% blasts in the marrow or blood)~* Patient is to be given targeted therapy. Examples of targeted therapies are tipifarnib + low-dose ara-C, decitabine, and 5 azacitidine + valproic acid.~* Age \>/= 60 years and Zubrod performance status of 0,1, or 2~* Informed consent obtained~Exclusion Criteria:~* Cannot receive ara-C at a dose \>/= 100 mg/m2 daily, anthracyclines, or cloretazine.

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Protective environment (Type: None): Participants in a Protective environment
- Not a protective environment (Type: None): Participants not in a protective environment

Based on this trial design, predict the completion outcome and termination type (if applicable).